Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors

被引:11
|
作者
Oyama, Rieko [1 ]
Kito, Fusako [1 ]
Takahashi, Mami [2 ]
Hattori, Emi [3 ]
Noguchi, Rei [3 ]
Takai, Yoko [1 ]
Sakumoto, Marimu [1 ]
Qiao, Zhiwei [3 ]
Toki, Shunichi [4 ]
Sugawara, Masato [4 ]
Tanzawa, Yoshikazu [4 ]
Kobayashi, Eisuke [4 ]
Nakatani, Fumihiko [4 ]
Iwata, Shintaro [4 ]
Yoshida, Akihiko [5 ,6 ]
Kawai, Akira [4 ]
Kondo, Tadashi [1 ,3 ]
机构
[1] Natl Canc Ctr, Res Inst, Dept Innovat Seeds Evaluat, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Res Inst, Cent Anim Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Res Inst, Div Rare Canc Res, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[4] Natl Canc Ctr, Div Musculoskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[5] Natl Canc Ctr, Dept Pathol, Chuo Ku, Tokyo 1040045, Japan
[6] Natl Canc Ctr, Clin Labs, Chuo Ku, Tokyo 1040045, Japan
关键词
Malignant peripheral nerve sheath tumor; Xenograft; Primary culture; Drug screening; PHASE-II; SOMATIC MUTATIONS; READ ALIGNMENT; TRANSFORMATION; SUZ12; PRC2;
D O I
10.1186/s12935-020-1128-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcomes for MPNST patients with unresectable or metastatic tumors are dismal, and novel therapeutic strategies are required. Although patient-derived cancer cell lines are vital for basic research and preclinical studies, few MPNST cell lines are available from public cell banks. Therefore, the aim of this study was to establish cancer cell lines derived from MPNST patients. Methods We used tumor tissues from five patients with MPNSTs, including one derived from a rare bone tissue MPNST. The tumor tissues were obtained at the time of surgery and were immediately processed to establish cell lines. A patient-derived xenograft was also established when a sufficient amount of tumor tissue was available. The characterization of established cells was performed with respect to cell proliferation, spheroid formation, and invasion. The mutation status of actionable genes was monitored by NCC Oncopanel, by which the mutation of 114 genes was assessed by next-generation sequencing. The response to anti-cancer agents, including anti-cancer drugs approved for the treatment of other malignancies was investigated in the established cell lines. Results We established five cell lines (NCC-MPNST1-C1, NCC-MPNST2-C1, NCC-MPNST3-C1, NCC-MPNST4-C1, and NCC-MPNST5-C1) from the original tumors, and also established patient-derived xenografts (PDXs) from which one cell line (NCC-MPNST3-X2-C1) was produced. The established MPNST cell lines proliferated continuously and formed spheroids while exhibiting distinct invasion abilities. The cell lines had typical mutations in the actionable genes, and the mutation profiles differed among the cell lines. The responsiveness to examined anti-cancer agents differed among cell lines; while the presence of an actionable gene mutation did not correspond with the response to the anticipated anti-cancer agents. Conclusion The established cell lines exhibit various characteristics, including proliferation and invasion potential. In addition, they had different mutation profiles and response to the anti-cancer agents. These observations suggest that the established cell lines will be useful for future research on MPNSTs.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Establishment and characterization of a recurrent malignant peripheral nerve sheath tumor cell line: RsNF
    Xingnan Zhang
    Chenhao Hu
    Dezhi Li
    Song Liu
    Human Cell, 2024, 37 : 345 - 355
  • [32] Establishment and genomic characterization of a sporadic malignant peripheral nerve sheath tumor cell line
    Jody Fromm Longo
    Stephanie N. Brosius
    Iya Znoyko
    Victoria A. Alers
    Dorea P. Jenkins
    Robert C. Wilson
    Andrew J. Carroll
    Daynna J. Wolff
    Kevin A. Roth
    Steven L. Carroll
    Scientific Reports, 11
  • [33] MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS OF THE SKIN
    GEORGE, E
    SWANSON, PE
    WICK, MR
    JOURNAL OF CUTANEOUS PATHOLOGY, 1987, 14 (06) : 356 - 356
  • [34] Malignant peripheral nerve sheath tumors in neurofibromatosis 1
    King, AA
    DeBaun, RR
    Riccardi, VM
    Gutmann, DH
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2000, 93 (05): : 388 - 392
  • [35] MAXILLOFACIAL MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS
    COLMENERO, C
    RIVERS, T
    PATRON, M
    SIERRA, I
    GAMALLO, C
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 1991, 19 (01) : 40 - 46
  • [36] Genetics of human malignant peripheral nerve sheath tumors
    Pemov, Alexander
    Li, Hua
    Presley, William
    Wallace, Margaret R.
    Miller, David T.
    NEURO-ONCOLOGY ADVANCES, 2020, 2 : i50 - i61
  • [37] Systemic Options for Malignant Peripheral Nerve Sheath Tumors
    Hassan, Ayesha
    Pestana, Roberto Carmagnani
    Parkes, Amanda
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (04)
  • [38] Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors
    Bodempudi, Vidya
    Yamoutpoor, Farnaz
    Pan, Weihong
    Dudek, Arkadiusz Z.
    Esfandyari, Tuba
    Piedra, Mark
    Babovick-Vuksanovic, Dusica
    Woo, Richard A.
    Mautner, Victor F.
    Kluwe, Lan
    Clapp, D. Wade
    DeVries, George H.
    Thomas, Stacey L.
    Kurtz, Andreas
    Parada, Luis F.
    Farassati, Faris
    MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (14) : 3964 - 3974
  • [39] A-Z of malignant peripheral nerve sheath tumors
    Kamran, S. C.
    Shinagare, A. B.
    Howard, S. A.
    Hornick, J. L.
    Ramaiya, N. H.
    CANCER IMAGING, 2012, 12 (03): : 475 - 483
  • [40] Systemic Options for Malignant Peripheral Nerve Sheath Tumors
    Ayesha Hassan
    Roberto Carmagnani Pestana
    Amanda Parkes
    Current Treatment Options in Oncology, 2021, 22